Iridium Therapeutics

Iridium Therapeutics was a private U.S. specialty pharmaceutical company focused on improving the delivery and adherence of established therapies rather than developing clearly disclosed novel molecular entities. Publicly available business-profile descriptions state that the company aimed to pair proven treatments with more convenient delivery technologies to improve outcomes, quality of life, and cost of care in severe or chronic medical conditions. The company appears to have operated from Cedar Grove, New Jersey, and was organized as Iridium Therapeutics LLC in 2017. Corporate registry data indicate the entity is no longer active and is listed as terminated or dissolved. Little reliable public information is available on a named pipeline, clinical-stage assets, investors, or partnerships, suggesting a very limited or stealth operating footprint.